MA40948A - Formulation de virus de l'herpès simplex congelée stable - Google Patents

Formulation de virus de l'herpès simplex congelée stable

Info

Publication number
MA40948A
MA40948A MA040948A MA40948A MA40948A MA 40948 A MA40948 A MA 40948A MA 040948 A MA040948 A MA 040948A MA 40948 A MA40948 A MA 40948A MA 40948 A MA40948 A MA 40948A
Authority
MA
Morocco
Prior art keywords
herpes simplex
simplex virus
virus formulation
stable frozen
frozen
Prior art date
Application number
MA040948A
Other languages
English (en)
Inventor
Bruce Arthur Kerwin
Jennifer R Litowski
Christine Claudia Siska
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA40948A publication Critical patent/MA40948A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composition de virus vivant qui maintient l'infectivité et améliore la stabilité du virus pendant un ou plusieurs cycles de congélation / décongélation et / ou au cours d'un stockage à long terme à l'état liquide à des températures comprises entre un point de congélation et la température ambiante.
MA040948A 2014-12-18 2015-12-15 Formulation de virus de l'herpès simplex congelée stable MA40948A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
MA40948A true MA40948A (fr) 2017-10-25

Family

ID=55229814

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040948A MA40948A (fr) 2014-12-18 2015-12-15 Formulation de virus de l'herpès simplex congelée stable

Country Status (19)

Country Link
US (2) US20170360857A1 (fr)
EP (1) EP3234114B9 (fr)
JP (2) JP6975041B2 (fr)
KR (2) KR102549746B1 (fr)
CN (1) CN107580626A (fr)
AU (2) AU2015362687B2 (fr)
BR (1) BR112017013009A2 (fr)
CA (1) CA2971201A1 (fr)
CL (1) CL2017001563A1 (fr)
CO (1) CO2017007086A2 (fr)
EA (1) EA201791382A1 (fr)
ES (1) ES2948037T3 (fr)
HK (1) HK1245823A1 (fr)
IL (3) IL308119A (fr)
MA (1) MA40948A (fr)
MX (2) MX2017008013A (fr)
SG (1) SG11201704975SA (fr)
WO (1) WO2016100364A1 (fr)
ZA (1) ZA201704695B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013419A1 (fr) * 2015-07-20 2017-01-26 Virttu Biologics Limited Utilisation d'un virus herpes simplex oncolytique, seul ou en combinaison avec un inhibiteur de point de contrôle immunitaire, dans le traitement du cancer
WO2019213509A1 (fr) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions et méthodes pour le traitement du cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
TW202039835A (zh) * 2018-12-27 2020-11-01 美商安進公司 凍乾病毒配製物
CN116209751A (zh) * 2020-07-07 2023-06-02 北京奥源和力生物技术有限公司 用于hsv-1基因编辑的指导rna及其方法
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
EP4442251A1 (fr) 2023-04-05 2024-10-09 Albumedix Ltd Formulations et leurs utilisations

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1141338A4 (fr) 1998-12-31 2002-09-25 Arch Dev Corp Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
EP3214175A1 (fr) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Anticorps ctla-4 humains et leurs utilisations
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1381280B1 (fr) 2001-03-27 2011-05-11 Catherex, Inc. Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
EP1456652A4 (fr) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
AU2003258060B2 (en) * 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
WO2006002394A2 (fr) 2004-06-24 2006-01-05 New York University Souches de virus d'herpes simplex oncolytique non virulent modifiees pour bloquer la reponse hote innee
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
EP2170959B1 (fr) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2998281C (fr) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1 humains et leurs utilisations
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
CA2802344C (fr) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
EP3246400B1 (fr) * 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification du virus de l'herpès
WO2013177172A2 (fr) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Compositions de virus herpétique et procédés associés
JP6457940B2 (ja) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法

Also Published As

Publication number Publication date
HK1245823A1 (zh) 2018-08-31
CL2017001563A1 (es) 2018-01-26
SG11201704975SA (en) 2017-07-28
AU2015362687A1 (en) 2017-07-06
EP3234114B1 (fr) 2023-04-12
JP2021072795A (ja) 2021-05-13
EP3234114B9 (fr) 2023-06-14
JP6975041B2 (ja) 2021-12-01
JP2018502078A (ja) 2018-01-25
IL300202A (en) 2023-03-01
IL308119A (en) 2023-12-01
EA201791382A1 (ru) 2017-10-31
MX2017008013A (es) 2018-03-06
IL300202B1 (en) 2023-12-01
US20170360857A1 (en) 2017-12-21
CA2971201A1 (fr) 2016-06-23
IL300202B2 (en) 2024-04-01
MX2023012564A (es) 2023-11-08
KR20170095270A (ko) 2017-08-22
ZA201704695B (en) 2023-12-20
EP3234114A1 (fr) 2017-10-25
KR102549746B1 (ko) 2023-07-03
IL252942A0 (en) 2017-08-31
WO2016100364A1 (fr) 2016-06-23
AU2022201523A1 (en) 2022-03-24
CN107580626A (zh) 2018-01-12
US20210052680A1 (en) 2021-02-25
CO2017007086A2 (es) 2017-10-10
KR20230107375A (ko) 2023-07-14
AU2015362687B2 (en) 2021-12-09
ES2948037T3 (es) 2023-08-30
BR112017013009A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
MA40948A (fr) Formulation de virus de l'herpès simplex congelée stable
DK3775092T3 (da) Stabiliserede fluoroolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf
DK3303958T3 (da) Massegodsfrysetørring ved anvendelse af sprøjtefrysning og tørring under omrøring med varme
DK3660151T5 (da) Protease-varianter med forbedret ydelse og lagerstabilitet
GB2576072B (en) Thermal Management Phase-Change Composition, Methods of Manufacture Thereof and Articles Containing the Composition
CO2017006981A2 (es) Composiciones herbicidas líquidas que contienen sulfonilurea
NI202100051A (es) Método de construcción para crear, en un sitio comercial, una laguna para el baño con playas de acceso restringido
FR3029355B1 (fr) Generateur thermoelectrique
EA201790945A1 (ru) Устройство и способы для маркировки пробирок или ампул, хранящихся при низких температурах до -200°c
DK3497085T3 (da) Sulfonamider som gpr40- og gpr120-agonister
CL2018002548A1 (es) Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
FR3050009B1 (fr) Cuve etanche et thermiquement isolante
CL2017001565A1 (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfurón.
UY36164A (es) Composiciones herbicidas sólidas que contienen un protector
EA201992813A1 (ru) Стабильная агрохимическая композиция и соответствующий процесс
Duarte de Krummel Importance of scientific research in university life
BR112016028662A2 (pt) composições herbicidas sólidas contendo um agente de proteção
UY38164A (es) Composiciones agroquímicas sólidas
DK3367030T3 (da) Isvitrine og isskuffer
RU2014120523A (ru) Адаптивный микронагревательный элемент с возможностью измерения температуры
RU2015133314A (ru) Белый шоколад с апельсином и облепихой
Arango Ríos ¿ Cómo afectan los sentidos al momento de degustar un alimento?: Proyecto de Grado
滕利华 et al. Effect of Quasi-Fermi Level on the Degree of Electron Spin Polarization in GaAs
DK3877709T3 (da) Frysere og køleskabe
Albaladejo Patrizia Battilani y harm G. SChröter (eds.), The Cooperative Business Movement, 1950 to the Present, Comparative Perspectives in Business history, Cambridge, Cambridge University Press, 2012, 291 pp.